OSE Stock Overview
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
OSE Immunotherapeutics SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €9.83 |
52 Week High | €9.95 |
52 Week Low | €3.12 |
Beta | 0.90 |
11 Month Change | 31.07% |
3 Month Change | 49.62% |
1 Year Change | 131.02% |
33 Year Change | 0.10% |
5 Year Change | 152.05% |
Change since IPO | -5.93% |
Recent News & Updates
OSE Immunotherapeutics SA (EPA:OSE) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 19Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings
Oct 04Recent updates
OSE Immunotherapeutics SA (EPA:OSE) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 19Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings
Oct 04Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?
May 23We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Oct 02We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Apr 30OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be
May 11Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?
May 08Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher
Mar 16How Is OSE Immunotherapeutics' (EPA:OSE) CEO Paid Relative To Peers?
Dec 01Shareholder Returns
OSE | FR Biotechs | FR Market | |
---|---|---|---|
7D | 7.1% | 3.8% | -0.2% |
1Y | 131.0% | -9.3% | 8.4% |
Return vs Industry: OSE exceeded the French Biotechs industry which returned -15.5% over the past year.
Return vs Market: OSE exceeded the French Market which returned 6.3% over the past year.
Price Volatility
OSE volatility | |
---|---|
OSE Average Weekly Movement | 10.0% |
Biotechs Industry Average Movement | 7.1% |
Market Average Movement | 4.5% |
10% most volatile stocks in FR Market | 9.4% |
10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: OSE's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: OSE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 52 | Nicolas Poirier | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
OSE fundamental statistics | |
---|---|
Market cap | €213.83m |
Earnings (TTM) | €46.03m |
Revenue (TTM) | €69.92m |
4.6x
P/E Ratio3.1x
P/S RatioIs OSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OSE income statement (TTM) | |
---|---|
Revenue | €69.92m |
Cost of Revenue | €0 |
Gross Profit | €69.92m |
Other Expenses | €23.88m |
Earnings | €46.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.12 |
Gross Margin | 100.00% |
Net Profit Margin | 65.84% |
Debt/Equity Ratio | 49.6% |
How did OSE perform over the long term?
See historical performance and comparison